Centre for Probe Development and Commercialization (CPDC) Appoints New Head of Business Development

November 16, 2018 CPDC

Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD.

Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as well as an impressive resume of business development expertise.

“This is a very exciting addition to the CPDC team,” stated Dr. Joe McCann, CEO of CPDC. “Bruno will lead the growth of our radiopharmaceutical imaging products business as well as provide business support to our contract services unit that is focused on regulatory affairs and clinical trial management. With Bruno’s knowledge and expertise, he will play a key role in keeping CPDC at the forefront of the industry.”

Bruno received his PhD in Biochemistry from Université de Montréal before conducting his post-doctoral research at the University of Albany. He became the Laboratory Director at Université de Montréal, Département de Biochimie, where he was responsible for the management and direction of a team of scientists. In 2000, he became the head of the Technology Development Unit at Genizon Biosciences Inc., where he was appointed the Executive Director, Head of Business Development.

In 2010, Bruno became a consultant for Business & Strategy Development in Life Sciences, Genetics and Pharmacogenomics for several organizations, and then went on to become VP of Business Development for Immuni T in Montréal in 2011. He has published extensively, is a named inventor in over 24 patent applications and has presented at international conferences.

Dr. Paquin stated, “I’m proud to become part of such an impressive organization that plays a major role in helping Canadians. I look forward to working alongside Dr. McCann and the rest of the team to extend the reach of CPDC products and services.”

About CPDC
The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.

Contacts
Centre for Probe Development and Commercialization
Angela Laurentani, 905 525-9140, ext. 21212
cpdc@imagingprobes.ca

More news from CPDC

CPDC executes its first commercial sublicensing agreement with Lawson Health Research Institute for PSMA-1007, expanding access to the prostate cancer diagnostic agent in Ontario

HAMILTON, ON, June 28, 2022 /CNW/ – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, has licensed [18F]PSMA-1007 from ABX- advanced biochemical compounds GmbH (Radeberg, Germany) and will hold the exclusive license to manufacture, commercialize and distribute the imaging agent in Canada. Concurrently, CPDC is also pleased to

Isotopia and CPDC Successfully Deliver First Doses of n.c.a. Lu-177 to North American Customers

Isotopia and CPDC shorten arrival time to patients. The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America.

The Centre for Probe Development and Commercialization expands into Asia and executes a development, manufacturing, and clinical supply agreement for 177Lu-PSMA (DGUL) With South Korea-based CellBion

HAMILTON, ON, May 25, 2022 – The Centre for Probe Development and Commercialization (CPDC) is pleased to announce the initiation of a development, manufacturing, and supply agreement with CellBion for Lu-177-radiolabelled PSMA (DGUL) therapeutic agent. Under the terms of the agreement, CPDC will develop and manufacture CellBion’s drug product for Phase II clinical supply in South Korea with the

For more information contact us at: